Despite the reports that monoclonal antibodies that directly inhibit PD-1 and PD-L1 have been a successful treatment options for advanced melanoma, non-small cell lung carcinoma (NSCLC), and some patients with high mutational burden like HNPCC colorectal cancer, limited success rate was noted in breast cancer clinical trials (53). This evidence concerns the gene CD274 and breast carcinoma.